Association Between Hypocomplementemia (C3 and C4) and MRI Findings in Different Neuropsychiatric Lupus Syndromes in a Tertiary Hospital

Yasser M. Bawazir 1, Sami Bahlas 1, Ibtisam Jali 2, Deyaa A. Mukhtar 3, Nujood Almohammadi 4, Mohammad Mustafa 5

1. Rheumatology/Internal Medicine, King Abdulaziz University Faculty of Medicine, Jeddah, SAU 2. Medicine, King Abdulaziz University Faculty of Medicine, Jeddah, SAU 3. Medicine, Hera General Hospital, Makkah, SAU 4. Medicine, King Fahad Hospital, Al Madinah, SAU 5. Rheumatology/Internal Medicine, University of Jeddah, Jeddah, SAU

Corresponding author: Yasser M. Bawazir, ymbawazir@kau.edu.sa

Abstract

Objective

The aim of this study was to describe the magnetic resonance imaging (MRI) findings and correlate them with the complements level.

Methodology

This is a retrospective chart review study involving 187 lupus patients attending the rheumatology clinic during the period between 2010 and 2020. Out of the 187 patients, only 49 patients were diagnosed to have neuropsychiatric lupus manifestation and underwent MRI study.

Results

We included 49 neuropsychiatric systemic lupus erythematosus patients with a mean age of 35.33 years; most of them were Saudi (51%), with disease duration between six and nine years (40.8%). In regard to MRI brain findings, 51% had abnormal findings, most commonly white matter changes in 42.9% followed by contrast enhancement in 36.7% and mild volume loss in 16.3%. Regarding the complement level, 21 (42.9%) patients had a low C3 level and 35 (71.4%) had a low C4 level. Lastly, following the main objective, C3 and C4 do not have a statistically significant relationship with white matter lesion given the sample of this data (p = 0.589 and p = 0.657, respectively).

Conclusion

MRI provides a significant clinical information to evaluate neuropsychiatric lupus manifestations. These clinical data can be correlated with immunological findings, which can help in the early diagnosis and management of this disease.

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disorder with various clinical presentations that affects many organ systems, including the central and peripheral nervous systems and muscles [1]. Neuropsychiatric SLE (NPSLE) is a life-threatening form of the disease; thus, early diagnosis and proper treatment are critical for the management of these patients. NPSLE can manifest with a range of neurological and psychiatric symptoms, as classified by the American College of Rheumatology (ACR) into 19 neuropsychiatric syndromes [2]. Approximately one-third of all NPSLE events in patients with SLE are primary manifestations of SLE-related autoimmunity, with seizure disorders, cerebrovascular disease, acute confusional state, and neuropathy being the most common [2].

Ahn et al. studied the possible risk factors for NPSLE in 1,121 patients with SLE of whom 429 developed NPSLE. They found that patients with a high SLE disease activity index, antiphospholipid antibody positivity, fewer years of education, and absence of anti-double strand deoxyribonucleic acid (anti-dsDNA) antibody at the time of diagnosis were at a higher risk of developing NPSLE [3].

The pathogenesis of NPSLE is poorly understood, and two theories have been proposed. Based on the blood-brain barrier (BBB) permeability theory, the BBB becomes more permeable to neuropathic antibodies, whereas the second theory suggests a defect in the blood-cerebrospinal fluid barrier in the choroid plexus,
which allows access of neuropathic antibodies to the nervous system and development of immune complexes [4].

Defective clearing of apoptotic material contributes to the formation of autoantibodies and immune complexes in SLE [5]. As the complement system is an important host mechanism for the removal of atypical antigens and immune complexes, hypocomplementemia in SLE is considered a serological sign of impending or ongoing inflammation where complement factors are “consumed” by tissue-bound immune complexes [6-8].

Despite their inclusion in SLE disease activity indices and classification criteria [9-10], the relationship between hypocomplementemia (C3 and C4), neuropsychiatric syndromes, and magnetic resonance imaging (MRI) findings has not been systematically investigated. It is unknown whether hypocomplementemia predicts neuropsychiatric lupus activity. In a cohort of 2,399 patients with SLE, 55% had low C3 levels and 47% had low C4 levels, and neuropsychiatric manifestations, including seizure, psychosis, and stroke, were significantly associated with both low C3 and C4 levels [11].

In this study, we aimed to investigate the relationship among hypocomplementemia, MRI findings, and neuropsychiatric manifestations in patients with NPSLE and establish the relative importance of radiological imaging findings in different NPSLE syndromes.

**Materials And Methods**

**Study design and patients**

This was a retrospective chart review study conducted at King Abdulaziz University Hospital in Jeddah, Saudi Arabia. We identified patients diagnosed with SLE based on the ACR criteria who were treated at the Rheumatology Clinic between 2010 and 2020. Pediatric patients, those with overlap syndrome, and those who did not fulfill the ACR criteria were excluded from the study. Patients who were presented with central nervous system (CNS) manifestation and fulfilled the ACR criteria for the diagnosis of neuropsychiatric lupus were identified and selected.

The study was approved by the Ethics Committee of King Abdulaziz University Hospital.

**Data collection**

Data were collected from the electronic medical record system of the hospital. The following data were recorded: demographic characteristics (age, nationality, and marital status), clinical features (diabetes mellitus, hypertension, disease duration, stage of nephritis, and NPSLE manifestations such as cerebrovascular disease, epilepsy, and mental disorder), and laboratory data (proteinuria, anti-phospholipid antibody, anti-nuclear antibody [ANA], anti-dsDNA, and complement levels).

Brain MRI scans obtained within six months after symptom onset were also evaluated. Brain MRI was performed for all patients using a 1.5 Tesla (SIGNA) machine (General Electric, Boston, MA, USA) following the standard procedures. The following sequences were obtained: T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and diffusion-weighted images. In some patients, gadolinium enhancement was performed on T1-weighted or fluid-attenuated inversion recovery images. The interpretation of the images was conducted by a neuroradiologist consultant at King Abdulaziz University Hospital.

**Outcome measures**

The primary outcome measures were the predictive role of immunological factors and their relationship with the brain MRI changes in NPSLE.

**Statistical analysis**

All data were analyzed using IBM SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, NY, USA) and visually presented using GraphPad Prism, version 8 (GraphPad Software, Inc., San Diego, CA, USA). Descriptive statistics was used to analyze the characteristics of the study patients. Categorical and nominal variables were presented as counts and percentages, and continuous variables were presented as means and standard deviations. To determine the correlation of white matter lesions, infarction, and brain atrophy with demographic and other variables, we used the chi-square test for categorical variables and the independent t-test for continuous variables with normal distribution. Otherwise, Welch’s t-test was used instead of the independent t-test. Finally, a conventional p-value of less than 0.05 was used to reject the null hypothesis. A private biostatistician was consulted to review the results.

**Results**

Of the identified 187 patients with SLE, only 49 (26.2%) were diagnosed with NPSLE based on the ACR criteria. Their mean age was 35.33±13.6 years, and 51% of them were Saudis, with a disease duration between six and nine years (40.8%) (Table 1).
TABLE 1: Patients’ demographic data.

| Demographics       | Number of patients | Minimum | Maximum | Mean  | SD   |
|--------------------|--------------------|---------|---------|-------|------|
| Age                | 49                 | 17      | 73      | 35.33 | 13.6 |
|                    | Count              |         |         |       |      |
| Nationality        |                    |         |         |       |      |
| Saudi              | 25                 |         |         | 51.0  |      |
| Non-Saudi          | 24                 |         |         | 49.0  |      |
| Disease duration   |                    |         |         |       |      |
| Less than 3 years  | 5                  |         |         | 10.2  |      |
| 3-6 years          | 10                 |         |         | 20.4  |      |
| 6-9 years          | 20                 |         |         | 40.8  |      |
| More than 9 years  | 14                 |         |         | 28.6  |      |
| Marital status     |                    |         |         |       |      |
| Single             | 31                 |         |         | 63.3  |      |
| Married            | 18                 |         |         | 36.7  |      |

With regard to the brain MRI findings, 51% of patients had abnormal findings, with the most common being white matter lesions (42.9%), followed by contrast enhancement (36.7%) and mild volume loss (16.3%) (Table 2).
| Variables                | Number of patients | %  |
|--------------------------|--------------------|----|
| Total                    | 49                 | 100.0 |
| MRI findings             |                    |     |
| Normal                   | 24                 | 49.0 |
| Abnormal                 | 25                 | 51.0 |
| Negative                 | 28                 | 57.1 |
| Positive                 | 21                 | 42.9 |
| Mild volume loss         |                    |     |
| Negative                 | 41                 | 83.7 |
| Positive                 | 8                  | 16.3 |
| Infarction               |                    |     |
| Negative                 | 47                 | 95.9 |
| Positive                 | 2                  | 4.1 |
| Sagittal thrombosis      |                    |     |
| Negative                 | 48                 | 98.0 |
| Positive                 | 1                  | 2.0 |
| Hemorrhage               |                    |     |
| Negative                 | 48                 | 98.0 |
| Positive                 | 1                  | 2.0 |
| PRES                     |                    |     |
| Negative                 | 47                 | 95.9 |
| Positive                 | 2                  | 4.1 |
| Contrast enhancement     |                    |     |
| Negative                 | 31                 | 63.3 |
| Positive                 | 18                 | 36.7 |

**TABLE 2: MRI findings in the study sample.**

PRES, Posterior reversible encephalopathy syndrome

ANA measured using the immunofluorescence technique was strongly positive in 73.5%, moderately positive in 20.4%, and mildly positive in 6.1% of patients. Regarding the anti-dsDNA status, 42 (85.7%) patients had a positive test with a high antibody level, and seven (14.3%) patients had a normal test. Moreover, 21 (42.9%) patients had low C3 levels and 35 (71.4%) had low C4 levels (Table 3). These levels were taken at the time of neurological symptoms.
### Variables

| Variables                      | Number of patients | Minimum | Maximum | Mean   | SD    |
|-------------------------------|--------------------|---------|---------|--------|-------|
| Anti-dsDNA level (ref: 0-200 IU/mg) | 49                 | 42      | 2,166   | 752.86 | 592.9 |
| CRP level (ref: <3.3 mg/dL)   | 23                 | 2.90    | 17.40   | 7.08   | 4.4   |
| Total                         | 49                 | N       | %       |        |       |

| ANA positivity                |                    |         |         |        |       |
|-------------------------------|--------------------|---------|---------|--------|-------|
| Mild (1/320)                  | 3                  |         | 6.1     |        |       |
| Moderate (1/640)              | 10                 |         | 20.4    |        |       |
| Strong (1/1,280)              | 36                 |         | 73.5    |        |       |

| Anti-dsDNA                    |                    |         |         |        |       |
|-------------------------------|--------------------|---------|---------|--------|-------|
| Normal                        | 7                  |         | 14.3    |        |       |
| Positive                      | 42                 |         | 85.7    |        |       |
| Low                           | 21                 |         | 42.9    |        |       |

| C3 level (ref: 0.75-1.65 g/L)  |                    |         |         |        |       |
|-------------------------------|--------------------|---------|---------|--------|-------|
| Normal                        | 24                 |         | 49.0    |        |       |
| High                          | 1                  |         | 2.0     |        |       |
| N/A                           | 3                  |         | 6.1     |        |       |
| Low                           | 35                 |         | 71.4    |        |       |

| C4 level (ref: 0.2-0.6 g/L)   |                    |         |         |        |       |
|-------------------------------|--------------------|---------|---------|--------|-------|
| Normal                        | 11                 |         | 22.4    |        |       |
| N/A                           | 3                  |         | 6.1     |        |       |

### TABLE 3: Autoantibody and complement levels in the study sample.

Anti-dsDNA, ant-double-strand deoxyribonucleic acid antibody; CRP, C-reactive protein; ANA, anti-nuclear antibody; C3, complement 3; C4, complement 4.

The most common NPSLE manifestation was headache (76.9%), followed by seizures (41%), stroke (15.4%), and psychosis (10.3%) (Table 4).

### TABLE 4: Neuropsychiatric manifestations reported in the study sample.

We identified 17 (34.7%) patients with proteinuria, and kidney biopsies were obtained from nine patients. The results showed class 3+5 nephritis in three patients, class 4 in one patient, and class 4+6 in one patient (Table 5). The majority of our patients did not have thromboembolic disease; however, two (4.1%) patients
had deep venous thrombosis and only one (2%) patient had chronic pulmonary embolism. Regarding chronic diseases, diabetes mellitus was reported in four (8.2%) patients and hypertension in 19 (38.8%) patients (Table 6).

| Variables                  | Count | %    |
|----------------------------|-------|------|
| **Total**                  | 49    | 100.0|
| Proteinuria                |       |      |
| Negative                   | 32    | 65.3 |
| Positive                   | 17    | 34.7 |
| Not done                   | 7     | 14.6 |
| Not indicated              | 29    | 60.4 |
| No indication for biopsy   | 2     | 4.2  |
| No biopsy results          | 1     | 2.1  |
| Mesangiproliferative       | 1     | 2.1  |
| **Nephritis stage**        |       |      |
| Focal proliferative        | 1     | 2.1  |
| Diffuse proliferative      | 2     | 4.2  |
| Class 4+6                  | 1     | 2.1  |
| Class 4                    | 1     | 2.1  |
| Class 3+5                  | 3     | 6.3  |
| Missing                    | 1     |      |
| **PT (ref: 11-14 seconds)**|       |      |
| Normal                     | 43    | 89.6 |
| High                       | 2     | 4.2  |
| N/A                        | 3     | 6.3  |
| Missing                    | 1     |      |
| **PTT (ref: 29-40 seconds)**|      |      |
| Normal                     | 38    | 79.2 |
| High                       | 7     | 14.6 |
| N/A                        | 3     | 6.3  |
| Missing                    | 1     |      |
| **Anti-cardiolipin IgM (ref: 0-12 IU/mL)** | | |
| Negative                   | 36    | 75.0 |
| Positive                   | 5     | 10.4 |
| Equivocal                  | 1     | 2.1  |
| Not done                   | 6     | 12.5 |
| Missing                    | 1     |      |
| **Anti-cardiolipin IgG (ref: 0-12 IU/mL)** | | |
| Negative                   | 33    | 71.7 |
| Positive                   | 3     | 6.5  |
| Not done                   | 10    | 21.7 |
| Missing                    | 3     |      |
| **Lupus anticoagulants (ref: >45)** | | |
| Negative                   | 32    | 69.6 |
| Positive                   | 4     | 8.5  |
| Not done                   | 5     | 10.6 |
| Missing                    | 2     |      |
| Beta 2 glycoprotein IgM (ref: 0-20 CU) |   |   |
|-------------------------------------|---|---|
| Not done                            | 14 | 30.4 |
| Missing                             | 3  |   |

| Beta 2 glycoprotein IgG (ref: 0-20 CU) |   |   |
|--------------------------------------|---|---|
| Negative                             | 32 | 68.1 |
| Not done                             | 14 | 29.8 |
| Equivocal                            | 1  | 2.1 |
| Missing                              | 2  |   |

**TABLE 5: Prevalence of lupus nephritis and antiphospholipid antibodies in the study sample.**

PT, prothrombin time; PTT, partial thromboplastin time
TABLE 6: Distribution of thromboembolic diseases and chronic metabolic disorders in the study sample.

DVT, deep venous thrombosis; PE, pulmonary embolism; DM, diabetes mellitus; LDL, low-density lipoprotein; HDL, high-density lipoprotein

| Variables                      | Count | %  |
|--------------------------------|-------|----|
| **Total**                      | 49    | 100.0|
| DVT                            |       |     |
| Not present                    | 43    | 87.8|
| Present                        | 2     | 4.1 |
| Sagittal venous thrombosis     | 2     | 4.1 |
| Mesenteric thrombosis          | 1     | 2.0 |
| Left femoral vein thrombosis   | 1     | 2.0 |
| PE                             |       |     |
| Not present                    | 48    | 98.0|
| Chronic PE                     | 1     | 2.0 |
| Abortion                       |       |     |
| No                             | 44    | 89.8|
| Yes                            | 1     | 2.0 |
| Unknown                        | 4     | 8.2 |
| DM                             |       |     |
| No                             | 45    | 91.8|
| Yes                            | 4     | 8.2 |
| Hypertension                   |       |     |
| No                             | 30    | 61.2|
| Yes                            | 19    | 38.8|
| Normal                         | 7     | 50.0|
| LDL (ref: 0-3.57 mmol/L)       |       |     |
| High                           | 2     | 14.3|
| N/A                            | 5     | 35.7|
| Missing                        | 35    |     |
| Low                            | 2     | 15.4|
| Normal                         | 1     | 7.7 |
| HDL (ref: 0.9-1.55 mmol/L)     |       |     |
| High                           | 4     | 30.8|
| N/A                            | 6     | 46.2|
| Missing                        | 36    |     |

In the multivariable analysis to determine the correlation between the MRI findings and demographic and clinical variables (Tables 7, 8), white matter lesions were the only MRI variable with sufficient representation and distribution to be included in correlation and regression models. Generally, all results were non-significant. However, patients with white matter lesions had a higher anti-dsDNA titer (904.24 IU/mL) compared with those without white matter lesions (639.32 IU/mL), although the difference was not statistically significant. Furthermore, white matter lesions were more prevalent among patients with strong ANA positivity than in those with a negative test, also without statistical significance (p = 0.054). Finally, C3 and C4 levels did not show a statistically significant relationship with white matter lesions (p = 0.589 and p = 0.657, respectively). Since no independent variables were identified as significant prognostic factors in this study sample, a regression model was not necessary for further analysis.
| Demographics          | Number of patients | White matter lesions | p-Value |
|-----------------------|--------------------|----------------------|---------|
|                       |                    | Negative            | Positive |         |
| Age (years)           | 49                 | 33.21±10.5          | 38.14±16.7 | 0.244 |
| Nationality           |                    |                     |         |         |
| Saudi                 | 25                 | 13 (52.0%)          | 12 (48.0%) | 0.458 |
| Non-Saudi             | 24                 | 15 (62.5%)          | 9 (37.5%)  |       |
| Disease duration      |                    |                     |         |         |
| Less than 3 years     | 5                  | 4 (80.0%)           | 1 (20.0%)  | 0.188 |
| 3-6 years             | 10                 | 8 (80.0%)           | 2 (20.0%)  |       |
| 6-9 years             | 20                 | 10 (50.0%)          | 10 (50.0%) |       |
| More than 9 years     | 14                 | 6 (42.9%)           | 8 (57.1%)  |       |
| Marital status        |                    |                     |         |         |
| Single                | 31                 | 18 (58.1%)          | 13 (41.9%) | 0.864 |
| Married               | 18                 | 10 (55.6%)          | 8 (44.4%)  |       |

**TABLE 7: Relationship between demographic factors and white matter lesions.**
| Variables                          | Total | White matter lesions | p-Value |
|-----------------------------------|-------|----------------------|---------|
|                                   |       | Negative             | Positive |
| Anti-dsDNA level (ref: 0-200 IU/mg) | 49    | 639.32±491.9         | 904.24±689.1 | 0.143        |
| CRP level (ref: <3.3 mg/dL)       |       | 49.95±4.7            | 7.29±4.1 | 0.862        |
| Mild (1/320)                      | 3     | 3 (100.0%)           | 0 (0.0%) |             |
| ANA positivity                    |       |                      |         |
| Moderate (1/640)                  | 10    | 8 (80.0%)            | 2 (20.0%) | 0.054        |
| Strong (1/1280)                   | 36    | 17 (47.2%)           | 19 (52.8%) |             |
| Anti-dsDNA                        |       |                      |         |
| Normal                            | 7     | 5 (71.4%)            | 2 (28.6%) | 0.409        |
| Positive                          | 42    | 23 (54.8%)           | 19 (45.2%) |             |
| C3 level (ref: 0.75-1.65 g/L)     |       |                      |         |
| Low                               | 21    | 10 (47.6%)           | 11 (52.4%) |             |
| Normal                            | 24    | 15 (62.5%)           | 9 (37.5%) | 0.589        |
| High                              | 1     | 1 (100.0%)           | 0 (0.0%) |             |
| N/A                               | 3     | 2 (66.7%)            | 1 (33.3%) |             |
| C4 level (ref: 0.2-0.6 g/L)       |       |                      |         |
| Low                               | 35    | 21 (60.0%)           | 14 (40.0%) |             |
| Normal                            | 11    | 5 (45.5%)            | 6 (54.5%) | 0.657        |
| N/A                               | 3     | 2 (66.7%)            | 1 (33.3%) |             |
| LDL (ref: 0-3.57 mmol/L)          |       |                      |         |
| Normal                            | 7     | 4 (57.1%)            | 3 (42.9%) |             |
| High                              | 2     | 0 (0.0%)             | 2 (100.0%) | 0.155        |
| N/A                               | 5     | 4 (80.0%)            | 1 (20.0%) |             |
| HDL (ref: 0.9-1.55 mmol/L)        |       |                      |         |
| Low                               | 2     | 0 (0.0%)             | 2 (100.0%) |             |
| Normal                            | 1     | 0 (0.0%)             | 1 (100.0%) |             |
| High                              | 4     | 3 (75.0%)            | 1 (25.0%) |             |
| N/A                               | 6     | 4 (66.7%)            | 2 (33.3%) |             |

**TABLE 8: Relationship between clinical variables and the incidence or prevalence of white matter lesions.**

Anti-dsDNA, anti-double strand DNA antibody; CRP, C-reactive protein; ANA, anti-nuclear antibody; C3, complement 3; C4, complement 4; LDL, low-density lipoprotein; HDL, high-density lipoprotein

**Discussion**

In this study, we found no significant correlation of the brain MRI findings with the demographic and clinical variables, including complement levels, in patients with NPSLE, although white matter lesions were more prevalent among patients with strong ANA positivity and higher anti-dsDNA titers.

NPSLE has heterogeneous clinical syndromes, and definitive diagnosis is challenging without clinical assessment, laboratory, and neuroradiological tests. Brain MRI specifically reveals multiple brain lesions; however, there is no MRI abnormality that is pathognomonic for NPSLE. The most commonly reported lesions are small vessel disease, particularly white matter hyperintensities and lacunar infarcts, large vessel disease, inflammatory-like lesions (i.e., multifocal gray matter lesions), and brain atrophy [12]. In our study, approximately half of the patients had abnormal MRI findings, most commonly white matter lesions, followed by contrast enhancement and mild volume loss. These findings are consistent with those of previous studies, in which white matter changes and brain atrophy were found to be common among patients with SLE with neuropsychiatric manifestations compared with healthy controls [13].

The hypothesis that MRI abnormalities in NPSLE correspond to certain neuropsychiatric syndromes and immunological patterns introduced the possibility of novel diagnostic, prognostic, or treatment response...
bilinear imaging (MRI) in the evaluation of various neuropsychiatric manifestations of systemic lupus erythematosus (SLE) and found that various complement components were associated with MRI findings. The associations were significant only when the complements and MRI findings were combined with antiphospholipid antibodies (aPLs) and lupus anticoagulants (LAs).

In the present study, we found a statistically significant correlation of low complement and lupus anticoagulant levels with inflammatory abnormalities, particularly stroke, psychosis, and severe headache. However, these results were limited by the small sample size and the retrospective design. The results suggest that there is a relationship between low complement levels and MRI findings in patients with NPSLE.

Conclusions
MRI provides significant clinical information for the evaluation of NPSLE manifestations. These clinical data can be correlated with immunological findings, aiding the early diagnosis and management of this disease. Low complement level did not associate with brain MRI findings in our patients.

Additional Information
Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Unit of Biomedical Ethics Research Committee issued approval 599-18. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICME uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Honczarenko K, Budzianowska A, Ostanek L: Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome. Neurologia i neurochirurgia polska. 2008, 42:513-7.
2. Bertiasz GK, Ioannidis JP, Aringer M, et al.: EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010, 69:2074-82. 10.1136/ard.2010.150476
3. Ahn GY, Kim D, Won S, et al.: Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus. 2018, 27:1338-47. 10.1177/0961203318772021
4. Stock AD, Gebh S, Pernstek M, Ben-Zvi A, Puttermann C: The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface. Autoimmun Rev. 2017, 16:612-9. 10.1016/j.autrev.2017.04.008
5. Pettigrew HD, Teuber SS, Gershwin ME: Clinical significance of complement deficiencies. Ann N Y Acad Sci. 2009, 1175:108-23. 10.1111/j.1749-6632.2009.04633.x
6. Truebsson L, Bengtsson AA, Sturfelt G: Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007, 40:560-6. 10.1080/08916930701510673
7. Barilla-LaBarca ML, Atkinson JP: Rheumatic syndromes associated with complement deficiency. Curr Opin Rheumatol. 2003, 15:55-60. 10.1097/0002221-200505000-00010
8. Walport MJ: Complement and systemic lupus erythematosus. Arthritis Res. 2002, 4 Suppl 5:S279-95. 10.1186/ar586
9. Petri M, Orbai AM, Alarcón GS, et al.: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012, 64:2677-86. 10.1002/art.34473
10. Aringer M, Costenbader K, Daikh D, et al.: 2019 European League Against Rheumatism/American College of...
Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019, 71:1400-12. 10.1002/art.40930

11. Durcan L, Petri M: The clinical and serological associations of hypocomplementemia in a longitudinal sle cohort. Semin Arthritis Rheum. 2020, 50:1081-6. 10.1016/j.semarthrit.2020.06.009

12. Ishikawa A, Okada J, Kondo H, Kashihara S: Abnormal findings of magnetic resonance imaging (MRI) in patients with systemic lupus erythematosus involving the brain. Ryumachi. 1992, 32:191-9.

13. Cannerfelt B, Nystedt J, Jönsen A, et al.: White matter lesions and brain atrophy in systemic lupus erythematosus patients: correlation to cognitive dysfunction in a cohort of systemic lupus erythematosus patients using different definition models for neuropsychiatric systemic lupus erythematosus. Lupus. 2018, 27:1140-9. 10.1177/0961203318763575

14. Toledano P, Sarbu N, Espinosa G, Bargalló N, Cervera R: Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev. 2013, 12:1166-70. 10.1016/j.autrev.2013.07.004

15. Wang HP, Wang CY, Pan ZL, Zhao JY, Zhao B: Relationship between clinical and immunological features with magnetic resonance imaging abnormalities in female patients with neuropsychiatric systemic lupus erythematosus. Chin Med J (Engl). 2016, 129:542-8. 10.4103/0366-6999.176996

16. Liu S, Cheng Y, Zhao Y, et al.: Hippocampal atrophy in systemic lupus erythematosus patients without major neuropsychiatric manifestations. J Immunol Res. 2020, 2020:2943848. 10.1155/2020/2943848

17. Sarbu N, Alobeidi F, Toledano P, et al.: Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev. 2015, 14:155-9. 10.1016/j.autrev.2014.11.001

18. Magro-Checa C, Schaarenburg RA, Beaart HI, Huizinga TW, Steup-Beekman GM, Trouw LA: Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. Lupus. 2016, 25:878-88. 10.1177/0961203316643170

19. Netto TM, Zimmermann N, Rueda-Lopes F, Bizoo BC, Fonseca RP, Gasparetto EL: Neuropsychiatric lupus: classification criteria in neuroimaging studies. Can J Neurol Sci. 2015, 40:284-91. 10.1017/s0317167100014219

20. Hanly JG, Urowitz MB, O’Keefe AG, et al.: Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013, 65:2887-97. 10.1002/art.38106